X4 Pharmaceuticals (XFOR) Scheduled to Post Quarterly Earnings on Wednesday

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. The business had revenue of $3.43 million during the quarter. On average, analysts expect X4 Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock traded up $0.02 during midday trading on Wednesday, reaching $0.58. 2,182,823 shares of the stock traded hands, compared to its average volume of 2,055,109. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. The firm has a fifty day moving average price of $0.60 and a two-hundred day moving average price of $0.78. The firm has a market cap of $97.54 million, a price-to-earnings ratio of 7.24 and a beta of 0.39. X4 Pharmaceuticals has a fifty-two week low of $0.47 and a fifty-two week high of $1.60.

Insider Buying and Selling at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, COO Mary Dibiase sold 67,695 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the transaction, the chief operating officer now directly owns 452,060 shares of the company's stock, valued at $257,674.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other X4 Pharmaceuticals news, COO Mary Dibiase sold 67,695 shares of the business's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the transaction, the chief operating officer now directly owns 452,060 shares of the company's stock, valued at $257,674.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paula Ragan sold 239,436 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $0.55, for a total transaction of $131,689.80. Following the sale, the chief executive officer now owns 1,057,713 shares in the company, valued at $581,742.15. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 580,800 shares of company stock valued at $321,447 in the last ninety days. Company insiders own 1.62% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.